Philip M - Search Results

1

Priming of naive T cells inside tumors leads to eradication of established tumors.

Yu P, Lee Y, Liu W, Chin RK, Wang J, Wang Y, Schietinger A, Philip M, Schreiber H, Fu YX. Yu P, et al. Among authors: philip m. Nat Immunol. 2004 Feb;5(2):141-9. doi: 10.1038/ni1029. Epub 2004 Jan 4. Nat Immunol. 2004. PMID: 14704792 Free article.

2

CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma.

Mumberg D, Monach PA, Wanderling S, Philip M, Toledano AY, Schreiber RD, Schreiber H. Mumberg D, et al. Among authors: philip m. Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8633-8. doi: 10.1073/pnas.96.15.8633. Proc Natl Acad Sci U S A. 1999. PMID: 10411927 Free PMC article.

3

Long-term suppression of tumor growth by TNF requires a Stat1- and IFN regulatory factor 1-dependent IFN-gamma pathway but not IL-12 or IL-18.

Wu TH, Pabin CN, Qin Z, Blankenstein T, Philip M, Dignam J, Schreiber K, Schreiber H. Wu TH, et al. Among authors: philip m. J Immunol. 2004 Mar 1;172(5):3243-51. doi: 10.4049/jimmunol.172.5.3243. J Immunol. 2004. PMID: 14978132

4

Inflammation as a tumor promoter in cancer induction.

Philip M, Rowley DA, Schreiber H. Philip M, et al. Semin Cancer Biol. 2004 Dec;14(6):433-9. doi: 10.1016/j.semcancer.2004.06.006. Semin Cancer Biol. 2004. PMID: 15489136 Review.

5

A mutant chaperone converts a wild-type protein into a tumor-specific antigen.

Schietinger A, Philip M, Yoshida BA, Azadi P, Liu H, Meredith SC, Schreiber H. Schietinger A, et al. Among authors: philip m. Science. 2006 Oct 13;314(5797):304-8. doi: 10.1126/science.1129200. Science. 2006. PMID: 17038624

6

Specificity in cancer immunotherapy.

Schietinger A, Philip M, Schreiber H. Schietinger A, et al. Among authors: philip m. Semin Immunol. 2008 Oct;20(5):276-85. doi: 10.1016/j.smim.2008.07.001. Epub 2008 Aug 5. Semin Immunol. 2008. PMID: 18684640 Free PMC article. Review.

7

Ribosomal versus non-ribosomal cellular antigens: factors determining efficiency of indirect presentation to CD4+ T cells.

Philip M, Schietinger A, Schreiber H. Philip M, et al. Immunology. 2010 Aug;130(4):494-503. doi: 10.1111/j.1365-2567.2010.03258.x. Epub 2010 Mar 16. Immunology. 2010. PMID: 20331471 Free PMC article.

8

Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase.

Schietinger A, Philip M, Liu RB, Schreiber K, Schreiber H. Schietinger A, et al. Among authors: philip m. J Exp Med. 2010 Oct 25;207(11):2469-77. doi: 10.1084/jem.20092450. Epub 2010 Oct 4. J Exp Med. 2010. PMID: 20921286 Free PMC article.

9

Beyond Genomics: Multidimensional Analysis of Cancer Therapy Resistance.

Philip M, Schietinger A. Philip M, et al. Trends Immunol. 2015 Nov;36(11):665-667. doi: 10.1016/j.it.2015.09.003. Epub 2015 Oct 1. Trends Immunol. 2015. PMID: 26440701 Free PMC article.

10

Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis.

Schietinger A, Philip M, Krisnawan VE, Chiu EY, Delrow JJ, Basom RS, Lauer P, Brockstedt DG, Knoblaugh SE, Hämmerling GJ, Schell TD, Garbi N, Greenberg PD. Schietinger A, et al. Among authors: philip m. Immunity. 2016 Aug 16;45(2):389-401. doi: 10.1016/j.immuni.2016.07.011. Epub 2016 Aug 9. Immunity. 2016. PMID: 27521269 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

350 results

Search Page